Posted in | News | Nanomedicine | Nanobusiness

Arrowhead Research Enters Option Agreement for Obesity-Treating Technology

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it.

The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas. Arrowhead sees the technology platform as an attractive candidate around which to form a new majority-owned subsidiary to steer the technology through clinical development.

“We’ve been tracking obesity and metabolic markets for some time and have been searching for technology with the potential of serving these markets in a unique and powerful way,” said Christopher Anzalone, Arrowhead’s CEO. “We believe the platform that Drs. Pasqualini and Arap have developed may represent a great leap forward in treating obesity, a condition with significant quality of life issues and virtually unparalleled direct and indirect economic costs. This is also a relatively advanced program from a development standpoint and could be ready to begin human clinical trials in the near term.”

The breakthrough approach was first published in the prestigious scientific journal Nature Medicine in May 2004 and received widespread media attention, including write-ups in the Wall Street Journal and the New York Times. Since 2004, Drs. Pasqualini and Arap have worked to refine the technology and complete preclinical efficacy and toxicity testing in preparation for clinical trials.

Source: http://www.arrowheadresearch.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, February 13). Arrowhead Research Enters Option Agreement for Obesity-Treating Technology. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=18992.

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead Research Enters Option Agreement for Obesity-Treating Technology". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=18992>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead Research Enters Option Agreement for Obesity-Treating Technology". AZoNano. https://www.azonano.com/news.aspx?newsID=18992. (accessed December 04, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead Research Enters Option Agreement for Obesity-Treating Technology. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=18992.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.